LENZ Therapeutics, Inc. filings document the company’s transition from ophthalmic product development to commercialization of VIZZ (aceclidine ophthalmic solution) 1.44% for presbyopia in adults. Form 8-K disclosures cover financial results, FDA approval and U.S. availability of VIZZ, product launch updates, safety-related communications, and capital-raising activity under an at-the-market sales agreement.
The company’s proxy and governance materials address shareholder voting matters, executive and board governance, material agreements, capital-structure disclosure, and operating and financial results. The filing record also captures regulatory and commercial disclosures tied to VIZZ, including product approval, launch-stage operations, financing transactions, and risk-related information relevant to a pharmaceutical company commercializing an ophthalmic prescription product.
BlackRock, Inc. files a Schedule 13G reporting beneficial ownership of 1,804,099 shares of Lenz Therapeutics common stock. The filing shows 1,804,099 shares beneficially owned, representing 5.8% of the class as of 03/31/2026, with sole voting power of 1,782,990 shares.
LENZ Therapeutics, Inc. shows multiple Squarepoint entities reporting beneficial ownership stakes in its common stock. Squarepoint Ops LLC, Squarepoint Capital LLP, Squarepoint Operations Private Limited and Squarepoint (DIFC) Ltd each report 1,593,246 shares (5.08%). Squarepoint Master Fund Limited reports 1,590,333 shares (5.07%) and Squarepoint Core Master Fund Limited reports 2,913 shares (0.01%).
The filing lists shared voting and shared dispositive power for these holdings and is signed by John Weitzer, Chief Compliance Officer, with signature dates of 04/08/2026.
LENZ Therapeutics director George Jeffrey P. reported an open-market purchase of common stock. On March 27, 2026, he bought 5,592 shares of LENZ Therapeutics, Inc. at a weighted average price of $8.9217 per share, within a price range of $8.80 to $9.12.
Following this transaction, he directly holds 5,592 shares of LENZ common stock. The filing notes that the total represents multiple individual trades aggregated into the reported weighted average price.
LENZ Therapeutics director and CEO Evert B. Schimmelpennink made an open-market purchase of 28,089 shares of Common Stock. The shares were bought on March 27, 2026 at a weighted average price of $8.9505 per share, within a price range of $8.80 to $9.25. Following this transaction, he directly owns 77,289 shares of LENZ Therapeutics Common Stock.
LENZ Therapeutics, Inc. Chief Financial Officer Daniel R. Chevallard reported an open-market purchase of 7,500 shares of common stock at $8.57 per share. Following this transaction, his direct holdings increased to 12,886 shares of LENZ common stock.
LENZ Therapeutics is a commercial-stage pharmaceutical company focused on vision therapies, centered on VIZZ, its once-daily eye drop for presbyopia. The FDA approved VIZZ on July 31, 2025 as the first and only aceclidine-based treatment, and U.S. commercialization began in late 2025.
Phase 3 CLARITY trials showed rapid, durable near-vision improvement, with many patients gaining three or more lines of near acuity without loss of distance vision and no serious treatment-related adverse events over more than 30,000 treatment days. Management estimates a U.S. self-pay market opportunity in excess of $3 billion, supported by high stated willingness to use daily drops.
The company is building a large prescriber base among eye care professionals and running a direct-to-consumer "Make it VIZZable" campaign with a sampling program and e-pharmacy fulfillment. LENZ holds patent protection on VIZZ into at least 2044 plus U.S. NCE exclusivity to July 2030, and has signed licensing and distribution deals covering Greater China, South Korea and Southeast Asia, Canada and the Middle East, while pursuing EMA approval and additional ex-U.S. partnerships.
LENZ Therapeutics reported its first commercial revenue in 2025 following the U.S. launch of VIZZ, its aceclidine-based eye drop for presbyopia. Product sales, net were $1.6 million for the fourth quarter and full year, reflecting initial uptake after FDA approval in July and launch in October.
Total 2025 revenue was $19.1 million, driven mainly by $17.5 million of ex-U.S. license payments and milestones. The company reported a 2025 net loss of $82.1 million, or $2.85 per share, as selling, general and administrative expenses rose to $91.1 million with the commercial build-out. Research and development spending declined to $18.7 million as late-stage trials concluded. LENZ ended 2025 with $292.3 million in cash, cash equivalents and marketable securities, which it expects to fund operations to post-launch positive operating cash flow.
Lenz Therapeutics, Inc. received an updated ownership report from Ridgeback Capital entities showing they no longer hold a meaningful stake in the company. In this Schedule 13G/A amendment, Ridgeback Capital Investments L.P. and related entities report beneficial ownership of 0 shares of Lenz common stock, representing 0.0% of the outstanding class as of the event date of 12/31/2025.
The filing confirms they have no sole or shared voting or dispositive power over any Lenz shares and that they now own 5% or less of the class. The reporting persons also certify that any securities referenced were not acquired and are not held for the purpose of changing or influencing control of Lenz Therapeutics.
FMR LLC and Abigail P. Johnson report significant passive ownership in LENZ THERAPEUTICS INC common stock. As of 12/31/2025, they beneficially owned 3,702,717.53 shares, representing 11.8% of the outstanding common stock, with sole dispositive power over these shares.
The filing states the position is held in the ordinary course of business and not to change or influence control of LENZ. Within this stake, Fidelity Growth Company Commingled Pool held 1,643,269.00 shares, or 5.3% of the total outstanding common stock at 12/31/2025.
BlackRock, Inc. filed an amended Schedule 13G reporting beneficial ownership of 1,537,723 shares of LENZ THERAPEUTICS, INC. common stock, representing 4.9% of the class as of the event date.
BlackRock reports sole power to vote 1,510,589 shares and sole power to dispose of 1,537,723 shares, with no shared voting or dispositive power. The filing states that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of LENZ Therapeutics.
The ownership reflects positions held by certain BlackRock business units, with various underlying persons entitled to dividends or sale proceeds, and no single such person holding more than five percent of the total outstanding common shares.